PPI interactions with clopidogrel

Medical Letter on Drugs and Therapeutics

Volumn 51, Issue 1303, 2009, Pages 2-3

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; ESOMEPRAZOLE; LANSOPRAZOLE; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; ANTITHROMBOCYTIC AGENT; ANTIULCER AGENT; DRUG DERIVATIVE; TICLOPIDINE;

CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; DRUG COST; DRUG INDICATION; GASTROESOPHAGEAL REFLUX; GASTROINTESTINAL HEMORRHAGE; HUMAN; PEPTIC ULCER; SHORT SURVEY; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; DRUG INTERACTION; INCIDENCE; REVIEW; STENT;

ANTI-ULCER AGENTS; CARDIOVASCULAR DISEASES; DRUG INTERACTIONS; GASTROESOPHAGEAL REFLUX; HUMANS; INCIDENCE; PEPTIC ULCER; PLATELET AGGREGATION INHIBITORS; PROTON PUMP INHIBITORS; STENTS; TICLOPIDINE;

EID: 58149383868     PISSN: 0025732X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Short Survey

References (9)

1. Antiplatelet and anticoagulant drugs. Treat Guidel Med Lett 2008; 6:29.
2. DL Bhatt et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents. J Am Coll Cardiol 2008; 52:1502.
3. XQ Li, et al. Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities. Drug Metab Dispos 2004; 32:821.
4. J-S Hulot et al. Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects. Blood 2006; 108:2244.
5. M Gilard et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, doubleblind OCLA (Omeprazole CLopidogrel Aspirin) study. J Am Coll Cardiol 2008; 51:256.
6. JM Siller-Matula et al. Effects of pantoprazole and esomeprazole on platelet inhibitions by clopidogrel. Am Heart J 2009; 157:148.
7. E Pezalla et al. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. J Am Coll Cardiol 2008; 52:1038.
8. RE Aubert et al. Understanding variability in antiplatelet drug effects in acute coronary syndromes. Abstract 3998: proton pump inhibitors effect on clopidogrel effectiveness: the clopidogrel medco outcomes study. Circulation 2008; 118:S-815.
9. SP Dunn et al. Understanding variability in antiplatelet drug effects in acute coronary syndromes. Abstract 3999: baseline proton pump inhibitor use is associated with increased cardiovascular events with and without the use of clopidogrel in the CREDO trial. Circulation 2008; 118:S-815.